GB0409703D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB0409703D0
GB0409703D0 GBGB0409703.6A GB0409703A GB0409703D0 GB 0409703 D0 GB0409703 D0 GB 0409703D0 GB 0409703 A GB0409703 A GB 0409703A GB 0409703 D0 GB0409703 D0 GB 0409703D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0409703.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0409703(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Priority to GBGB0409703.6A priority Critical patent/GB0409703D0/en
Publication of GB0409703D0 publication Critical patent/GB0409703D0/en
Priority to EP05738040A priority patent/EP1755555B1/en
Priority to SG200903001-6A priority patent/SG152292A1/en
Priority to JP2007510045A priority patent/JP5000483B2/ja
Priority to SG10201605001SA priority patent/SG10201605001SA/en
Priority to CA2563760A priority patent/CA2563760C/en
Priority to EP11190637.6A priority patent/EP2422766B1/en
Priority to CN201710357916.6A priority patent/CN107252423A/zh
Priority to SI200531570T priority patent/SI1755555T1/sl
Priority to KR1020067024763A priority patent/KR101287919B1/ko
Priority to ES11190637.6T priority patent/ES2546982T3/es
Priority to HUE11190637A priority patent/HUE025463T2/en
Priority to PT05738040T priority patent/PT1755555E/pt
Priority to PT111906376T priority patent/PT2422766E/pt
Priority to BRPI0510500A priority patent/BRPI0510500B8/pt
Priority to NZ550479A priority patent/NZ550479A/en
Priority to SG2012093886A priority patent/SG186673A1/en
Priority to ES05738040T priority patent/ES2388289T3/es
Priority to CNA200580013592XA priority patent/CN1964700A/zh
Priority to AU2005237266A priority patent/AU2005237266B2/en
Priority to PL05738040T priority patent/PL1755555T3/pl
Priority to MXPA06012493A priority patent/MXPA06012493A/es
Priority to SI200531999T priority patent/SI2422766T1/sl
Priority to DK11190637.6T priority patent/DK2422766T3/da
Priority to EP11190638A priority patent/EP2422767A3/en
Priority to PCT/EP2005/051980 priority patent/WO2005105043A2/en
Priority to US11/587,725 priority patent/US20080063719A1/en
Priority to DK05738040.4T priority patent/DK1755555T3/da
Priority to HK07102081.9A priority patent/HK1095282B/en
Priority to PL11190637T priority patent/PL2422766T3/pl
Priority to RU2006142322/15A priority patent/RU2396943C2/ru
Priority to CN2010105642463A priority patent/CN102008453A/zh
Priority to IL178651A priority patent/IL178651A/en
Priority to MX2012008068A priority patent/MX341426B/es
Priority to ZA2006/09350A priority patent/ZA200609350B/en
Priority to NO20065502A priority patent/NO20065502L/no
Priority to AU2011200543A priority patent/AU2011200543B2/en
Priority to JP2011244443A priority patent/JP5124718B2/ja
Priority to CY20121100722T priority patent/CY1113069T1/el
Priority to HK12108085.5A priority patent/HK1167334B/en
Priority to IL223545A priority patent/IL223545A/en
Priority to HUS1300006C priority patent/HUS1300006I1/hu
Priority to LU92176C priority patent/LU92176I2/fr
Priority to CY2013012C priority patent/CY2013012I2/el
Priority to LU92392C priority patent/LU92392I2/xx
Priority to CY2014015C priority patent/CY2014015I1/el
Priority to CY20151100754T priority patent/CY1116655T1/el
Priority to LTPA2015053C priority patent/LTC2422766I2/lt
Priority to HUS1500072C priority patent/HUS1500072I1/hu
Priority to HUS1500073C priority patent/HUS1500073I1/hu
Priority to CY2015060C priority patent/CY2015060I1/el
Priority to CY2015059C priority patent/CY2015059I1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0409703.6A 2004-04-30 2004-04-30 Pharmaceutical compositions Ceased GB0409703D0 (en)

Priority Applications (52)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
EP05738040A EP1755555B1 (en) 2004-04-30 2005-04-29 Methods for preparing dry powder compositions of glycopyrrolate
SG200903001-6A SG152292A1 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions
JP2007510045A JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物
SG10201605001SA SG10201605001SA (en) 2004-04-30 2005-04-29 Pharmaceutical compositions
CA2563760A CA2563760C (en) 2004-04-30 2005-04-29 Pharmaceutical compositions comprising glycopyrrolate
EP11190637.6A EP2422766B1 (en) 2004-04-30 2005-04-29 Dry powder compositions of glycopyrrolate and magnesium stearate
CN201710357916.6A CN107252423A (zh) 2004-04-30 2005-04-29 药物组合物
SI200531570T SI1755555T1 (sl) 2004-04-30 2005-04-29 Postopek za pripravo sestavka suhega prahu glikopirolata
KR1020067024763A KR101287919B1 (ko) 2004-04-30 2005-04-29 약학적 조성물
ES11190637.6T ES2546982T3 (es) 2004-04-30 2005-04-29 Composiciones de polvo seco de glicopirrolato y estearato magnésico
HUE11190637A HUE025463T2 (en) 2004-04-30 2005-04-29 Dry powder compositions of glycopyrrolate and magnesium stearate
PT05738040T PT1755555E (pt) 2004-04-30 2005-04-29 Método para a produção composições farmacêuticas de pó seco de glicopirrolato
PT111906376T PT2422766E (pt) 2004-04-30 2005-04-29 Composições de pó seco de glicopirrolato e estearato de magnésio
BRPI0510500A BRPI0510500B8 (pt) 2004-04-30 2005-04-29 formulação de pó seco, seu método de preparação e dispositivo de inalação de pó seco
NZ550479A NZ550479A (en) 2004-04-30 2005-04-29 A stable dry powder formulation comprising glycopyrrolate and magnesium stearate
SG2012093886A SG186673A1 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions
ES05738040T ES2388289T3 (es) 2004-04-30 2005-04-29 Método para preparar composiciones de polvo seco de glicopirrolato
CNA200580013592XA CN1964700A (zh) 2004-04-30 2005-04-29 药物组合物
AU2005237266A AU2005237266B2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions
PL05738040T PL1755555T3 (pl) 2004-04-30 2005-04-29 Sposoby wytwarzania kompozycji w postaci suchego proszku z glikopirolanem
MXPA06012493A MXPA06012493A (es) 2004-04-30 2005-04-29 Composiciones farmaceuticas.
SI200531999T SI2422766T1 (sl) 2004-04-30 2005-04-29 Suhi praškasti sestavki iz glikopirolata in magnezijevega stearata
DK11190637.6T DK2422766T3 (da) 2004-04-30 2005-04-29 Tørpulversammensætninger af glycopyrrolat og magnesiumstearat
EP11190638A EP2422767A3 (en) 2004-04-30 2005-04-29 Methods for preparing dry powder compositions of glycopyrrolate
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions
US11/587,725 US20080063719A1 (en) 2004-04-30 2005-04-29 Pharmaceutical Compositions
DK05738040.4T DK1755555T3 (da) 2004-04-30 2005-04-29 Fremgangsmåde til fremstilling af tørpulversammensætninger af glycopyrrolat
HK07102081.9A HK1095282B (en) 2004-04-30 2005-04-29 Methods for preparing dry powder compositions of glycopyrrolate
PL11190637T PL2422766T3 (pl) 2004-04-30 2005-04-29 Kompozycje glikopirolanu i stearynianu magnezu w postaci suchego proszku
RU2006142322/15A RU2396943C2 (ru) 2004-04-30 2005-04-29 Фармацевтические композиции
CN2010105642463A CN102008453A (zh) 2004-04-30 2005-04-29 药物组合物
IL178651A IL178651A (en) 2004-04-30 2006-10-16 Dry powder formulations for inhalation comprising glycopyrrolate and methods for preparing the same
MX2012008068A MX341426B (es) 2004-04-30 2006-10-27 Metodos para preparar composiciones en polvo seco de glicopirrolato.
ZA2006/09350A ZA200609350B (en) 2004-04-30 2006-11-10 Pharmaceutical compositions
NO20065502A NO20065502L (no) 2004-04-30 2006-11-29 Farmasoytiske sammensetninger.
AU2011200543A AU2011200543B2 (en) 2004-04-30 2011-02-09 Pharmaceutical compositions
JP2011244443A JP5124718B2 (ja) 2004-04-30 2011-11-08 医薬組成物
CY20121100722T CY1113069T1 (el) 2004-04-30 2012-08-13 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
HK12108085.5A HK1167334B (en) 2004-04-30 2012-08-16 Dry powder compositions of glycopyrrolate and magnesium stearate
IL223545A IL223545A (en) 2004-04-30 2012-12-10 A method of preparing an inhalant containing dry powder of glycopyrolate and magnesium strat
HUS1300006C HUS1300006I1 (hu) 2004-04-30 2013-03-13 Eljárás glikopirrolát száraz por készítmények elõállítására
LU92176C LU92176I2 (fr) 2004-04-30 2013-03-27 Glycopyrronium ou un de ses sels
CY2013012C CY2013012I2 (el) 2004-04-30 2013-03-29 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης τουγλυκοπυρρολικου
LU92392C LU92392I2 (fr) 2004-04-30 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulèrement le sel bromure, combiné à indacatérol ou un sel de celui-ci, plus particlièrement le sel maléate
CY2014015C CY2014015I1 (el) 2004-04-30 2014-03-19 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY20151100754T CY1116655T1 (el) 2004-04-30 2015-08-27 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
LTPA2015053C LTC2422766I2 (lt) 2004-04-30 2015-12-18 Glikopirolato ir magnio stearato sausų miltelių kompozicijos
HUS1500072C HUS1500072I1 (hu) 2004-04-30 2015-12-21 Glikopirrolát és magnézium-sztearát száraz por kompozíciói
HUS1500073C HUS1500073I1 (hu) 2004-04-30 2015-12-21 Glikopirrolát és magnézium-sztearát száraz por kompozíciói
CY2015060C CY2015060I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015059C CY2015059I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB0409703D0 true GB0409703D0 (en) 2004-06-02

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0409703.6A Ceased GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions

Country Status (26)

Country Link
US (1) US20080063719A1 (enExample)
EP (3) EP2422766B1 (enExample)
JP (2) JP5000483B2 (enExample)
KR (1) KR101287919B1 (enExample)
CN (3) CN1964700A (enExample)
AU (2) AU2005237266B2 (enExample)
BR (1) BRPI0510500B8 (enExample)
CA (1) CA2563760C (enExample)
CY (6) CY1113069T1 (enExample)
DK (2) DK1755555T3 (enExample)
ES (2) ES2388289T3 (enExample)
GB (1) GB0409703D0 (enExample)
HU (4) HUE025463T2 (enExample)
IL (2) IL178651A (enExample)
LT (1) LTC2422766I2 (enExample)
LU (2) LU92176I2 (enExample)
MX (2) MXPA06012493A (enExample)
NO (1) NO20065502L (enExample)
NZ (1) NZ550479A (enExample)
PL (2) PL1755555T3 (enExample)
PT (2) PT2422766E (enExample)
RU (1) RU2396943C2 (enExample)
SG (3) SG10201605001SA (enExample)
SI (2) SI1755555T1 (enExample)
WO (1) WO2005105043A2 (enExample)
ZA (1) ZA200609350B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2234595B1 (en) * 2007-12-13 2012-11-28 Novartis AG Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
US20100266696A1 (en) * 2007-12-13 2010-10-21 Gerhard Muhrer Organic Compounds
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP5809985B2 (ja) 2009-02-26 2015-11-11 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤
CA2759041A1 (en) * 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
RU2012138909A (ru) * 2010-03-31 2014-05-10 Гленмарк Фармасьютикалс Лимитед Фармацевтическая порошковая композиция для ингаляций
RU2585101C2 (ru) * 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
HUE038555T2 (hu) 2010-04-21 2018-10-29 Chiesi Farm Spa Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására
AU2011298315B2 (en) 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US20140275517A1 (en) * 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
CA2963146A1 (en) * 2014-10-16 2016-04-21 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CA3016368A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
KR102762199B1 (ko) 2016-03-08 2025-02-07 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
US11219602B2 (en) 2017-03-15 2022-01-11 Vectura Limited Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
PL3585383T3 (pl) 2017-12-11 2021-07-05 Mereo Biopharma 1 Limited Zastosowanie 3-[5-amino-4-(3-cyjanobenzoilo)pirazol-1-ilo]- n-cyklopropylo- 4-metylobenzamidu w zapobieganiu ostrym zaostrzeniom przewlekłej obturacyjnej choroby płuc
ES2884789T3 (es) 2017-12-11 2021-12-13 Mereo Biopharma 1 Ltd Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en el tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
US20250058063A1 (en) 2021-12-21 2025-02-20 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118414147A (zh) 2021-12-21 2024-07-30 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
AU2211502A (en) * 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
PT2283817T (pt) 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
JP2005530765A (ja) * 2002-05-07 2005-10-13 ネクター セラピューティクス 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用

Also Published As

Publication number Publication date
BRPI0510500B8 (pt) 2021-05-25
IL223545A (en) 2016-04-21
ES2546982T3 (es) 2015-09-30
LU92176I2 (fr) 2013-05-27
CN102008453A (zh) 2011-04-13
IL178651A (en) 2012-12-31
RU2006142322A (ru) 2008-06-20
PT2422766E (pt) 2015-10-12
AU2005237266B2 (en) 2010-11-11
EP2422767A2 (en) 2012-02-29
EP1755555A2 (en) 2007-02-28
LU92176I9 (enExample) 2019-01-04
CY2014015I2 (el) 2015-12-09
SG152292A1 (en) 2009-05-29
CN107252423A (zh) 2017-10-17
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
US20080063719A1 (en) 2008-03-13
SG10201605001SA (en) 2016-08-30
AU2011200543B2 (en) 2012-11-29
MX341426B (es) 2016-08-18
ZA200609350B (en) 2008-04-30
EP2422767A3 (en) 2012-04-25
HUS1500073I1 (hu) 2016-02-29
NZ550479A (en) 2009-11-27
PL1755555T3 (pl) 2012-11-30
JP2007535522A (ja) 2007-12-06
JP5000483B2 (ja) 2012-08-15
HUE025463T2 (en) 2016-02-29
IL223545A0 (en) 2013-02-03
SI1755555T1 (sl) 2012-10-30
HUS1300006I1 (hu) 2016-07-28
PT1755555E (pt) 2012-08-17
SG186673A1 (en) 2013-01-30
AU2005237266A1 (en) 2005-11-10
CA2563760A1 (en) 2005-11-10
LTC2422766I2 (lt) 2020-02-10
WO2005105043A2 (en) 2005-11-10
RU2396943C2 (ru) 2010-08-20
PL2422766T3 (pl) 2015-11-30
SI2422766T1 (sl) 2015-10-30
AU2011200543A8 (en) 2011-03-31
WO2005105043A3 (en) 2006-05-04
CA2563760C (en) 2013-07-02
LU92392I2 (fr) 2015-11-02
EP2422766A3 (en) 2012-04-25
CY1116655T1 (el) 2017-03-15
JP5124718B2 (ja) 2013-01-23
CY2013012I1 (el) 2015-08-05
HK1167334A1 (en) 2012-11-30
CY2015060I1 (el) 2020-05-29
DK1755555T3 (da) 2012-08-20
HUS1500072I1 (hu) 2016-02-29
BRPI0510500B1 (pt) 2019-04-24
JP2012031209A (ja) 2012-02-16
EP2422766A2 (en) 2012-02-29
CY2014015I1 (el) 2015-12-09
CY2015059I1 (el) 2020-05-29
KR20070033978A (ko) 2007-03-27
HK1095282A1 (en) 2007-05-04
AU2011200543A1 (en) 2011-03-03
EP1755555B1 (en) 2012-05-23
BRPI0510500A (pt) 2007-10-30
MXPA06012493A (es) 2007-01-29
NO20065502L (no) 2007-01-24
CY2013012I2 (el) 2015-08-05
DK2422766T3 (da) 2015-08-31
CY1113069T1 (el) 2015-08-05
ES2388289T3 (es) 2012-10-11
KR101287919B1 (ko) 2013-07-18
CN1964700A (zh) 2007-05-16

Similar Documents

Publication Publication Date Title
IL223545A0 (en) Pharmaceutical compositions
ZA200700030B (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL177480A0 (en) Pharmaceutical composition
IL188352A0 (en) Pharmaceutical compositions
IL183986A0 (en) Pharmaceutical compounds and compositions
GB0405033D0 (en) Novel pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
GB0406378D0 (en) Novel pharmaceutical compositions
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
IL192091A0 (en) Pharmaceutical compositions
GB0406380D0 (en) Novel pharmaceutical compositions
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0425255D0 (en) Pharmaceutical composition
ZA200701932B (en) Pharmaceutical composition
GB0522045D0 (en) Pharmaceutical compositions
ZA200701931B (en) Pharmaceutical composition
GB0407351D0 (en) Pharmaceutical compositions
GB0400971D0 (en) Pharmaceutical compositions
GB0411502D0 (en) Pharmaceutical compositions
GB0502792D0 (en) Pharmaceutical compositions
GB0514259D0 (en) Pharmaceutical compositions
ZA200803566B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)